The association of anticoagulant effects of warfarin with polymorphisms of genes in pharmacokinetic and pharmacodynamic pathway

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCC-10000778

Enrollment

Unknown

Registered

2009-12-02

Start date

2009-03-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart valve replacement

Interventions

Total:Warfarin and concomitant interacting medications, Genotypes

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Chinese patients with heart valve replacement and with warfarin treatment

Exclusion criteria

Exclusion criteria: pregnancy

Design outcomes

Primary

Measure	Time frame
INR;	—

Secondary

Measure	Time frame
Bleeding and thromboembolic complication;	—

Countries

China

Contacts

Public ContactShuguang Lin

yuxycn@163.com+86 20 83827812-21180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026